2160 related articles for article (PubMed ID: 18310199)
21. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
Klein NP; Weston WM; Kuriyakose S; Kolhe D; Howe B; Friedland LR; Van Der Meeren O
Vaccine; 2012 Jan; 30(3):668-74. PubMed ID: 22064267
[TBL] [Abstract][Full Text] [Related]
22. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.
Guerra FA; Gress J; Werzberger A; Reisinger K; Walter E; Lakkis H; Grosso AD; Welebob C; Kuter BJ;
Pediatr Infect Dis J; 2006 Oct; 25(10):912-9. PubMed ID: 17006287
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants.
Deichmann KA; Ferrera G; Tran C; Thomas S; Eymin C; Baudin M
Vaccine; 2015 May; 33(20):2379-86. PubMed ID: 25765966
[TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
Vesikari T; Karvonen A; Smith HM; Dunning A; Razmpour A; Saville MK; Gruber WC; Forrest BD
Pediatrics; 2008 Mar; 121(3):e568-73. PubMed ID: 18299305
[TBL] [Abstract][Full Text] [Related]
25. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
Shinefield HR; Black S; Kuter BJ
J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
Leung JH; Hirai HW; Tsoi KK
Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
[TBL] [Abstract][Full Text] [Related]
27. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children.
Shinefield HR; Black SB; Staehle BO; Matthews H; Adelman T; Ensor K; Li S; Chan I; Heyse J; Waters M; Chan CY; Vessey SJ; Kaplan KM; Kuter BJ;
Pediatr Infect Dis J; 2002 Jun; 21(6):555-61. PubMed ID: 12182381
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers.
Klein NP; Shepard J; Bedell L; Odrljin T; Dull P
Vaccine; 2012 Jun; 30(26):3929-36. PubMed ID: 22504039
[TBL] [Abstract][Full Text] [Related]
30. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
Nolan T; McIntyre P; Roberton D; Descamps D
Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
[TBL] [Abstract][Full Text] [Related]
32. Combination measles, mumps, rubella and varicella vaccine.
Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients.
Kawano Y; Suzuki M; Kawada J; Kimura H; Kamei H; Ohnishi Y; Ono Y; Uchida H; Ogura Y; Ito Y
Vaccine; 2015 Mar; 33(12):1440-5. PubMed ID: 25665961
[TBL] [Abstract][Full Text] [Related]
34. Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin.
Rüger G; Gabutti G; Rümke H; Rombo L; Bernaola E; Diez-Domingo J; Martinon-Torres F; Høgh B; Konstantopoulos A; Fiquet A; Thomas S; Eymin C; Baudin M
Pediatr Infect Dis J; 2012 Nov; 31(11):1166-72. PubMed ID: 22772170
[TBL] [Abstract][Full Text] [Related]
35. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age.
Stück B; Stehr K; Bock HL
Asian Pac J Allergy Immunol; 2002 Jun; 20(2):113-20. PubMed ID: 12403196
[TBL] [Abstract][Full Text] [Related]
36. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine.
Vesikari T; Sadzot-Delvaux C; Rentier B; Gershon A
Pediatr Infect Dis J; 2007 Jul; 26(7):632-8. PubMed ID: 17596807
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P
Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096
[TBL] [Abstract][Full Text] [Related]
39. A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.
Marshall GS; Senders SD; Shepard J; Twiggs JD; Gardner J; Hille D; Hartzel J; Valenzuela R; Stek JE; Helmond FA
Hum Vaccin Immunother; 2016 Aug; 12(8):2188-2196. PubMed ID: 27149048
[TBL] [Abstract][Full Text] [Related]
40. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
